logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line

< Back

Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line

Drugs

Cancer and Palliative Care

October 2020


Ipatasertib in addition to abiraterone and prednisone is in clinical development for the first line treatment of metastatic castrate resistant prostate cancer (mCRPC). Prostate cancer is a cancer of the prostate gland and mCRPC is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. The symptoms of prostate cancer may vary depending on the stage but can include pain, tiredness, and problems emptying the bladder and the bowels. Treatment options for mCRPC are currently limited.
Ipatasertib is an oral, highly specific medicine designed to target and bind to all three forms of protein called AKT. By binding to AKT, ipatasertib blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. If licensed, ipatasertib in addition to abiraterone and prednisone will provide a new regimen for mCRPC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts